In the last decade, prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) became the first-choice imaging for the restaging of biochemical recurrence (BCR) of prostate cancer (PCa) [1]. This evidence concerns the gene FOLH1 and prostate cancer.